Understanding Heart Attacks: A Complete Guide by Dr. Damian Rasch

What a heart attack actually is

A heart attack, or myocardial infarction, happens when blood flow to part of your heart muscle stops. That section starts dying, and the clock runs against you from the first minute.

Three coronary arteries wrap around your heart like a crown and feed a muscle that beats about 100,000 times a day. Over years, cholesterol and inflammatory cells build into plaque inside the artery wall, a process called atherosclerosis. The artery stretches to accommodate it, so you feel nothing. Then a plaque cracks, your body sends platelets to seal it the way it would a cut finger, and that repair becomes a clot that closes the vessel in minutes.

Heart muscle tolerates about 20 to 30 minutes of complete blockage before cells start dying. By six hours most of the muscle downstream is scar, which doesn’t contract. Coronary arteries carry few backup routes, called collateral circulation, so when one closes there’s no detour. Heart disease is still the leading cause of death in the United States, ahead of cancer, accidents, and respiratory disease combined.

Common misconceptions and fears

A 45-year-old teacher had crushing chest pain running down her left arm. A 68-year-old with diabetes felt unusually tired and short of breath while gardening. Both were having serious heart attacks, and their symptoms were completely different.

Women, people with diabetes, older patients, and people with kidney disease often have no chest pain at all, which is how these get written off as indigestion, a pulled muscle, or a panic attack. Pain that comes and goes still counts, and any new or unusual chest discomfort deserves immediate evaluation.

Unless you’re allergic to aspirin or actively bleeding, chew an aspirin while you wait for the ambulance. The dose is 325 mg, four baby aspirins or one regular-strength tablet, and it keeps the clot from growing on the way in.

Heart attacks happen under 40. Smoking, cocaine, certain medications, genetic conditions, and severe stress can trigger one at any age. Others are silent, found later on an electrocardiogram (EKG) or imaging, and they carry the same long-term risk as the ones you feel.

The five types

Type 1 is the classic heart attack, plaque rupture with a clot blocking the artery, and it accounts for about 85% of them. These need the artery reopened urgently, with clot-busting drugs or emergency angioplasty.

Type 2 is a supply and demand mismatch with no sudden clot. Severe infection, uncontrolled high blood pressure, a racing rhythm, or severe anemia pushes the workload past what partly narrowed arteries can supply. An 82-year-old develops pneumonia that runs her heart rate at 140 beats per minute for hours. Her moderate blockages were fine at rest and can’t keep up. Her troponin rises, and treatment focuses on the pneumonia and the heart rate rather than opening arteries. Anti-clotting drugs can do harm in Type 2, especially when bleeding caused the anemia that triggered it.

Type 3 is sudden cardiac death in someone with heart attack symptoms who dies before blood tests confirm it, despite CPR and advanced life support. Autopsy sometimes shows an acute coronary blockage.

Types 4 and 5 are procedure-related. Type 4a happens during or shortly after angioplasty or stenting, 4b is a clot in a previously placed stent, 4c is gradual re-narrowing of a stented artery, and Type 5 relates to bypass surgery.

STEMI, NSTEMI, and unstable angina

Acute coronary syndrome covers three conditions along one spectrum.

Unstable angina is new or worsening chest discomfort, often at rest or with minimal activity, lasting longer than your usual angina and sometimes not easing with nitroglycerin. Blood tests show no muscle death. It’s your heart’s warning shot.

NSTEMI means real damage, confirmed by elevated troponin, a protein found only in heart muscle cells. No ST-elevation on the EKG, which points to partial or intermittent closure.

STEMI means the artery is completely blocked. The EKG shows ST-elevation in specific leads, a large area of muscle is in immediate danger, and we want that artery open within 90 minutes of your arrival.

Unstable angina can feel identical to a STEMI, which is why the emergency department goes straight to troponin and an EKG. STEMI goes to immediate catheterization. NSTEMI gets risk-stratified, high risk to the cath lab within 24 hours and lower risk scheduled over a few days. Unstable angina we monitor closely, sometimes with a procedure on a less urgent timeline.

The tests, and what the numbers mean

The EKG comes first because it’s fast and painless, and ST-elevation tells us which artery is blocked and which wall is at risk. A normal EKG doesn’t rule out a heart attack. Many NSTEMIs look normal at first, so we repeat it every few hours. EKGs also miss heart attacks in the back wall or smaller arteries, and a baseline abnormality can hide new changes.

Troponin is our most sensitive marker of heart muscle injury. It starts rising within 3 to 4 hours and stays up as long as two weeks, so a very early draw can read normal and needs repeating. High-sensitivity assays detect tiny amounts of damage, which cuts both ways. A troponin of 0.050 ng/mL sounds alarming and means minimal damage if the normal range tops out at 0.045 ng/mL. A troponin of 2.5 ng/mL can mean a small heart attack in one person and a large one in another, depending on body size and kidney function. Troponin also rises in kidney disease, severe infection, and heart failure. Creatine kinase (CK-MB) rises too, less sensitive and slower, and I use it when troponin is unclear or I’m sorting out repeat events.

An echocardiogram shows how well your heart squeezes and which walls move poorly. Your ejection fraction, the percentage of blood pumped out with each beat, normally runs 55-70%. Below 40% is meaningfully reduced.

Cardiac catheterization is the gold standard for seeing the arteries. We thread a thin tube from your wrist or groin up to the heart and inject contrast dye under X-ray. It can’t tell us which plaque will rupture next, and plenty of heart attacks come from blockages that looked moderate earlier. Stability decides that, not size, and no imaging measures stability reliably. Stress tests miss roughly 10-15% of serious blockages, especially in smaller arteries or when someone can’t exercise hard enough. I weigh symptoms, exam, EKG, and labs together.

What raises your risk

Men’s risk climbs from around age 45, women’s after menopause, usually near 55. A father with a heart attack before 55 or a mother before 65 raises yours substantially.

Diabetes ages arteries early and brings heart disease 10-15 years sooner, often silently. Blood pressure over 140/90 mmHg raises risk clearly, and even 130-139/80-89 mmHg carries some. Elevated LDL cholesterol supplies the raw material for plaque while HDL pulls cholesterol back out of artery walls, so your total number tells you less than the breakdown. About half of heart attack patients have normal or only moderately elevated cholesterol, so a clean lipid panel is not a clean bill of health. Smoking inflames arteries, thickens blood, and speeds plaque, and quitting cuts your risk roughly in half within a year. Thirty minutes of moderate activity most days does real work. Abdominal obesity drives inflammation and travels with diabetes, hypertension, and bad lipids. Depression roughly doubles heart attack risk, and chronic stress raises blood pressure and cortisol. Sleep apnea raises risk through repeated overnight oxygen drops. Rheumatoid arthritis and other chronic inflammatory conditions raise it too, and air pollution contributes less than the traditional factors.

Risk factors multiply rather than add. Diabetes plus high blood pressure plus smoking doesn’t triple your risk, it compounds it, which is why fixing several at once pays off out of proportion.

How we treat it

For STEMI, door-to-balloon time is the number we live by, 90 minutes or less from arrival to an open artery. Primary angioplasty threads a balloon-tipped catheter to the blockage, crushes the clot, and usually leaves a stent, a small metal mesh tube, to hold the vessel open. Where immediate angioplasty isn’t available, thrombolytic therapy dissolves the clot intravenously. It carries bleeding risk, works less well than angioplasty, and has to go in within 12 hours of symptom onset, ideally the first few.

Everyone with acute coronary syndrome gets antiplatelet therapy. Aspirin goes in immediately unless you’re allergic, and on its own it cuts death risk about 20-25%. We add clopidogrel, prasugrel, or ticagrelor for dual antiplatelet therapy, choosing on bleeding risk, kidney function, and your other medications. Heparin or bivalirudin prevents further clotting during initial treatment. Beta-blockers slow the heart and cut its workload. ACE inhibitors or ARBs limit remodeling of the muscle afterward. Statin therapy starts immediately whatever your cholesterol reads, since statins stabilize plaque and calm inflammation on top of lowering LDL, and after a heart attack that usually means atorvastatin 80mg or rosuvastatin 40mg.

Coronary artery bypass grafting (CABG) takes over when several arteries are severely blocked or the left main is critically narrowed. Surgeons build new routes with vessels from your chest, leg, or arm. Recovery runs longer than after angioplasty and the result is often more complete and durable. The choice turns on the number and location of blockages, your health, your life expectancy, and what you want. Some patients do best with a hybrid of both.

When a standard treatment is the wrong treatment

Thrombolytics are off the table with recent surgery, active bleeding, a history of hemorrhagic stroke, or severe uncontrolled high blood pressure. Consider a patient with a clear STEMI who’d fallen and hit his head the day before. Clot-busters would risk a brain bleed, so that patient goes for emergency angioplasty instead.

Antiplatelet drugs need caution with active bleeding, a recent stomach ulcer, or a bleeding disorder, and they raise bleeding risk in the stomach and brain even when we do use them, though the risk from the heart attack usually outweighs that and we rarely withhold them outright. Beta-blockers get avoided in severe asthma, certain rhythm abnormalities, and decompensated heart failure, they can mask low blood sugar in a diabetic on insulin, and they cause fatigue and sexual dysfunction in some people. ACE inhibitors are wrong in severe kidney disease, prior angioedema, or pregnancy, and a persistent dry cough or worsening kidney function drives some patients off them. Statins occasionally cause muscle pain and rarely serious muscle damage.

Catheterization can be inappropriate in severe dementia or when life expectancy is measured in weeks. Angioplasty on a chronic total occlusion closed for months often fails, and medication or bypass handles it better. Stents commit you to dual antiplatelet therapy for at least a year, so if you can’t take those drugs or have surgery coming, angioplasty alone or bypass may fit better. Bypass carries prohibitive risk with severe lung disease, kidney failure, or several prior cardiac operations.

Age by itself decides nothing. Function and life expectancy decide. A sharp 90-year-old with no other serious illness can do well with aggressive treatment, and a 70-year-old with advanced dementia and failing organs will not. Cardiogenic shock may need mechanical circulatory support before angioplasty, and cardiac arrest survivors may need targeted temperature management after resuscitation. Your own preferences count too, including refusal of blood products.

What treatment can and can’t deliver

Stents treat a blockage. They don’t cure the disease that built it, new blockages form elsewhere, and about 5-10% of patients need a repeat procedure within a year, usually for restenosis. Stopping dual antiplatelet therapy early is the dangerous mistake here. It sharply raises the risk of stent thrombosis, a clot inside the stent that causes a massive heart attack. Take those drugs the full year or longer, exactly as prescribed.

Bypass carries risks of bleeding, infection, stroke, and kidney injury, and grafts don’t last forever. Vein grafts typically run 10-15 years, arterial grafts often past 20. Risk calculators give a population average, not a personal verdict. Lifestyle changes guarantee nothing either. Medicine improves odds, it doesn’t sell guarantees, and treated fast, many patients end up with very little lasting injury.

Recovery, and the part nobody warns you about

Cardiac rehabilitation is one of the best-supported things we offer, and fewer than half of eligible patients go. Programs run 12-36 sessions over 3-4 months with supervised exercise, education, stress management, and nutrition counseling, and the group does as much good as the treadmill.

Statins are usually lifelong. Blood pressure and diabetes medications need adjusting as you heal and move more. Expect blood tests every few months at first for cholesterol, kidney function, and liver enzymes, an echocardiogram to see whether heart function recovers, and for some patients an annual stress test. Quitting smoking after a heart attack cuts your risk of death by about 50% in the first year, which beats any pill I can write. If you snore loudly, stop breathing in your sleep, or wake up exhausted, get evaluated for sleep apnea. Learn the warning signs, find out which hospital near you runs a 24-hour cardiac catheterization lab, and keep your medication list where your family can find it.

The emotional side blindsides people. Denial is harmless right up until it stops you taking your medication. Depression hits about a third of heart attack patients, and this is clinical depression, not sadness. It raises the risk of another cardiac event and of death, so tell me about persistent sadness, loss of interest, sleep trouble, fatigue, or hopelessness. Anxiety about the next one is near universal. Full recovery takes months, and counseling, cardiac rehab, and support groups all help.

Ask for numbers in absolute terms as you go. A drug that cuts your risk 30% sounds different once you know your risk was 10% a year and is now 7%. Bring someone to appointments, since almost nobody remembers a cardiology consultation cleanly. Second opinions are appropriate for big decisions, especially bypass surgery, and an advance directive plus a conversation with your family carries real weight when choices get made in minutes. Ask about generics and assistance programs if cost is a problem, and about clinical trials if standard treatment hasn’t worked. Between visits, read the American Heart Association, the American College of Cardiology, and Mayo Clinic.

What’s coming

Genetic testing already flags patients who don’t metabolize clopidogrel well, so we can pick a different antiplatelet up front. Coronary CT angiography read with artificial intelligence, plus optical coherence tomography and intravascular ultrasound in the cath lab, is getting better at spotting plaque likely to rupture. Newer antiplatelets and anticoagulants aim for the same protection with less bleeding. Stem cell and gene therapies are in trials with mixed early results. AI now reads EKGs and echocardiograms, wearables track rhythm between visits, transcatheter aortic valve replacement reshaped valve care, robotic-assisted surgery shortened recovery, and polypills may improve adherence. Coronary artery calcium scoring finds risk before symptoms, and high-sensitivity CRP flags people who may benefit from anti-inflammatory treatment.

None of it displaces the basics. Don’t smoke, move most days, eat well, control your blood pressure and blood sugar, take your medications, keep your weight reasonable. And time is still the whole game. Don’t delay seeking care if you have symptoms that could represent a heart attack. The sooner treatment begins, the more heart muscle we can save.

References

1. Rao, Sunil V., et al. “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.” Journal of the American College of Cardiology (2025): S0735-1097(24)10424-X.

2. Kontos, Michael C., et al. “2022 ACC Expert Consensus Decision Pathway on the Evaluation and Disposition of Acute Chest Pain In the Emergency Department.” Journal of the American College of Cardiology 80, no. 20 (2022): 1925-1960.

3. Damluji, Abdulla A., et al. “Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association.” Circulation 147, no. 3 (2023): e32-e62.

4. DeFilippis, Andrew P., et al. “Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury.” Circulation 140, no. 20 (2019): 1661-1678.

5. Thygesen, Kristian, et al. “Fourth Universal Definition of Myocardial Infarction (2018).” Circulation 138, no. 20 (2018): e618-e651.

6. Cohen, Marc, and Geetha Visveswaran. “Defining and Managing Patients With Non-St-Elevation Myocardial Infarction: Sorting Through Type 1 vs Other Types.” Clinical Cardiology 43, no. 3 (2020): 242-250.

7. Anderson, Jeffrey L., and David A. Morrow. “Acute Myocardial Infarction.” The New England Journal of Medicine 376, no. 21 (2017): 2053-2064.

8. Bhatt, Deepak L., Renato D. Lopes, and Robert A. Harrington. “Diagnosis and Treatment of Acute Coronary Syndromes: A Review.” JAMA 327, no. 7 (2022): 662-675.

9. Ibanez, Borja, et al. “2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.” European Heart Journal 39, no. 2 (2018): 119-177.

10. Collet, Jean-Philippe, et al. “2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.” European Heart Journal 42, no. 14 (2021): 1289-1367.

11. Lawton, Jennifer S., et al. “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization.” Journal of the American College of Cardiology 79, no. 2 (2022): e21-e129.

12. Piepoli, Massimo F., et al. “2016 European Guidelines on cardiovascular disease prevention in clinical practice.” European Heart Journal 37, no. 29 (2016): 2315-2381.